Methods of manufacturing anamorelin tablets having improved stability
WO2020183240A1
Continuous process for producing benzimidazole derivatives
KR20200097762A
(R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methyl Piperidin-4-yl) fumarate salt of urea, its preparation method, and uses
EP3542799A1
New centrally-active ghrelin agonist and medical uses thereof
EP3381886A1
A process for producing carboxylic acids from tertiary alcohols under continuous flow
EP3435980A1
Physiologically balanced injectable formulations of fosnetupitant
KR20180128930A
Benzenesulfonyl-asymmetric ureas and their medical uses
US2017096442A1
Crystalline forms of fosnetupitant
US2017087216A1
Therapeutic Uses of Elsiglutide
US2016046667A1
Crystal forms of anamorelin
TW201613888A
Crystalline forms of an NK-1 antagonist
US2016067311A1
Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
KR20170047372A
Medical treatments based on anamorelin
TW201946901A
P-substituted asymmetric ureas and medical uses thereof
US2013261592A1
Liquid pharmaceutical formulations of palonosetron
US2015011510A1
4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
JO3202B1
Substituted 4-phenyl-pyridines for the treatment of nk-1 receptor related diseases
CN106974912A
The Therapeutic combinations of Netupitant and palonosetron
ZA201203174B
Compositions for treating centrally mediated nausea and vomiting
AU2012202164A1
Stabilized compositions of volatile alkylating agents and methods of using thereof
